NETRF funded Dr. Renuka Iyer to launch a Phase I trial of SurVaxM, a vaccine targeting survivin, a protein driving NET progression. This approach offers hope for slowing progression and improving outcomes for neuroendocrine cancer.

Home » NETRF funded Dr. Renuka Iyer to launch a Phase I trial of SurVaxM, a vaccine targeting survivin, a protein driving NET progression. This approach offers hope for slowing progression and improving outcomes for neuroendocrine cancer.